Related Experiment Video

Updated: Apr 21, 2026

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging
11:14

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging

Published on: April 6, 2014

11.9K

Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials

Shruti V Kabadi1, Alan I Faden1

  • 1Department of Anesthesiology, Center for Shock, Trauma and Anesthesiology Research (STAR), University of Maryland School of Medicine, Baltimore, MD, USA.

Neural Regeneration Research
|November 5, 2014
PubMed

Insights

Cyclin-dependent kinase inhibitors show significant neuroprotection after traumatic brain injury (TBI). These drugs reduce neuronal death, inflammation, and dysfunction, offering a promising therapeutic window for TBI treatment.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Traumatic brain injury (TBI) causes secondary injury, leading to neuroinflammation, neuronal loss, and dysfunction.
  • Cell cycle activation is a key mechanism in TBI-induced neuronal apoptosis and glial activation.

Purpose of the Study:

  • To evaluate the neuroprotective effects of cyclin-dependent kinase (CDK) inhibitors in experimental TBI models.
  • To assess the therapeutic window and potential clinical applicability of CDK inhibitors for TBI.

Main Methods:

  • Utilized multiple experimental traumatic brain injury models across different species.
  • Administered non-selective (Flavopiridol) and selective (Roscovitine, CR-8) CDK inhibitors as single systemic doses up to 24 hours post-TBI.

Main Results:

  • CDK inhibitors demonstrated significant neuroprotective effects.
  • Reduced neuronal cell death, neuroinflammation, and neurological dysfunction were observed.
  • A long therapeutic window was established for CDK inhibitor administration.

Conclusions:

  • CDK inhibitors offer robust neuroprotection following TBI.
  • Their effectiveness and extended therapeutic window make them promising candidates for clinical TBI trials.
Keywords:
CR-8Roscovitinebehaviorcell cycle inhibitionlateral fluid percussionmicroglial activationneurodegeneration

More Related Videos

Controlled Cortical Impact Model of Mouse Brain Injury with Therapeutic Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Cells09:29

Controlled Cortical Impact Model of Mouse Brain Injury with Therapeutic Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Cells

Published on: July 10, 2019

10.6K
Controlled Cortical Impact Model for Traumatic Brain Injury05:30

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

28.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Traumatic Brain Injury l: Introduction01:28

Traumatic Brain Injury l: Introduction

DefinitionTraumatic brain injury, or TBI, is a disturbance of normal brain function induced by an external mechanical force, such as a direct blow to the head or a penetrating injury. It can affect both brain structure and function, producing a wide range of clinical outcomes. TBI is a heterogeneous condition, meaning its effects may differ based on the type, location, and severity of the injury.Basis of ClassificationTBI is classified based on severity, injury mechanism, or pathophysiology. In...
2
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K